PMS-ASA TABLET

Երկիր: Կանադա

Լեզու: անգլերեն

Աղբյուրը: Health Canada

Ակտիվ բաղադրիչ:

ACETYLSALICYLIC ACID

Հասանելի է:

PHARMASCIENCE INC

ATC կոդը:

B01AC06

INN (Միջազգային անվանումը):

ACETYLSALICYLIC ACID

Դոզան:

81MG

Դեղագործական ձեւ:

TABLET

Կազմը:

ACETYLSALICYLIC ACID 81MG

Կառավարման երթուղին:

ORAL

Միավորները փաթեթում:

100/500

Ռեկվիզորի տեսակը:

OTC

Թերապեւտիկ տարածք:

SALICYLATES

Ապրանքի ամփոփագիր:

Active ingredient group (AIG) number: 0101169013; AHFS:

Լիազորման կարգավիճակը:

APPROVED

Հաստատման ամսաթիվը:

2006-07-19

Ապրանքի հատկությունները

1
PRODUCT MONOGRAPH
PMS-ASA
(Acetylsalicylic acid chewable tablets, USP)
81 mg
PRAXIS ASA EC 81 MG DAILY LOW DOSE
(Acetylsalicylic acid delayed-release tablets, USP)
81 mg
Platelet aggregation inhibitor
Pharmascience, Inc
Date of Preparation:
6111 Royalmount Ave # 100
July 18, 2006
Montreal, Quebec
Date of Revision:
H4P 2T4
July 30, 2009
CONTROL NO
. 131594
2
PRODUCT MONOGRAPH
PMS-ASA
(Acetylsalicylic acid chewable tablets, USP)
81 mg
PRAXIS ASA EC 81 MG DAILY LOW DOSE
(Acetylsalicylic acid delayed release tablets, USP)
81 mg
THERAPEUTIC OR PHARMACOLOGICAL CLASSIFICATION
Platelet aggregation inhibitor.
ACTION AND CLINICAL PHARMACOLOGY
ASA interferes with the production of prostaglandins in various organs
and tissues through
acetylation of the enzyme cyclo-oxygenase. Prostaglandins are
themselves powerful irritants and
produce headaches and pain on injection in man. Prostaglandins also
appear to sensitize pain
receptors to other noxious substances such as histamine and
bradykinin. By preventing the
synthesis and release of prostaglandins in inflammation, ASA may avert
the sensitization of pain
receptors.
The antipyretic activity of ASA is due to its ability to interfere
with the
production of
prostaglandin E
1
in the brain. Prostaglandin E
1
is one of the most powerful pyretic agents
known.
The inhibition of platelet aggregation by ASA is due to its ability to
interfere with the production
of
thromboxane A
2
within
the
platelet.
Thromboxane A
2
is
largely
responsible
for
the
aggregating properties of platelets.
3
INDICATIONS AND CLINICAL USE
Acetylsalicylic acid (ASA) is indicated for the following uses, based
on its platelet aggregation
inhibitory properties:
-For reducing the risk of morbidity and death in patients with
unstable angina and in those
with previous myocardial infarction.
-For reducing the risk of transient ischemic attacks (TIA) and for
secondary prevention of
atherothrombotic cerebral infarction;
In addition, pms-ASA 81 mg and Praxis ASA EC 81 mg Daily Low Dose 81
mg are also
indicated for the fol